These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33115620)
21. Disease severity in subsequent pregnancies with RhD immunization: A nationwide cohort. Zwiers C; Slootweg YM; Koelewijn JM; Ligthart PC; van der Bom JG; van Kamp IL; Lopriore E; van der Schoot CE; Oepkes D; de Haas M Vox Sang; 2024 Aug; 119(8):859-866. PubMed ID: 38772910 [TBL] [Abstract][Full Text] [Related]
22. Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy. Londero D; Merluzzi S; Dreossi C; Barillari G Blood Transfus; 2023 Mar; 21(2):93-99. PubMed ID: 35848630 [TBL] [Abstract][Full Text] [Related]
23. Frequency and clinical significance of red cell antibodies in pregnancy - A prospective study from India. Das S; Shastry S; Rai L; Baliga PB Indian J Pathol Microbiol; 2020; 63(2):241-246. PubMed ID: 32317523 [TBL] [Abstract][Full Text] [Related]
24. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334 [TBL] [Abstract][Full Text] [Related]
25. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland. Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198 [TBL] [Abstract][Full Text] [Related]
26. Routine noninvasive prenatal screening for fetal Rh D in maternal plasma-A 2-year experience from a single center in Belgium. Blomme S; Nollet F; Rosseel W; Bogaard N; Devos H; Emmerechts J; Cauwelier B Transfusion; 2022 May; 62(5):1103-1109. PubMed ID: 35352833 [TBL] [Abstract][Full Text] [Related]
27. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. Szczepura A; Osipenko L; Freeman K BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652 [TBL] [Abstract][Full Text] [Related]
29. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn]. Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074 [TBL] [Abstract][Full Text] [Related]
30. Non-invasive prenatal diagnosis of fetal RhD by using free fetal DNA. Gönenç G; Işçi H; Yiğiter AB; Hançer V; Büyükdoğan M; Güdücü N; Dünder I Clin Exp Obstet Gynecol; 2015; 42(3):344-6. PubMed ID: 26152007 [TBL] [Abstract][Full Text] [Related]
31. The use of maternal plasma for prenatal RhD blood group genotyping. Finning K; Martin P; Daniels G Methods Mol Biol; 2009; 496():143-57. PubMed ID: 18839110 [TBL] [Abstract][Full Text] [Related]
32. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Daniels G; Finning K; Martin P; Soothill P Vox Sang; 2004 Nov; 87(4):225-32. PubMed ID: 15585017 [TBL] [Abstract][Full Text] [Related]
33. Algorithm development and diagnostic accuracy testing for non-invasive foetal RHD genotyping: an Indian experience. Parchure D; Madkaikar M; Kulkarni S Blood Transfus; 2022 May; 20(3):235-244. PubMed ID: 33819144 [TBL] [Abstract][Full Text] [Related]
34. Title: Effect of multiple maternal red cell alloantibodies on the occurrence and severity of Hemolytic Disease of the Fetus and Newborn. Singh B; Chaudhary R; Katharia R Transfus Apher Sci; 2021 Feb; 60(1):102958. PubMed ID: 33039278 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. Chitty LS; Finning K; Wade A; Soothill P; Martin B; Oxenford K; Daniels G; Massey E BMJ; 2014 Sep; 349():g5243. PubMed ID: 25190055 [TBL] [Abstract][Full Text] [Related]
36. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme. Slootweg YM; Koelewijn JM; van Kamp IL; van der Bom JG; Oepkes D; de Haas M BJOG; 2016 May; 123(6):955-63. PubMed ID: 26661943 [TBL] [Abstract][Full Text] [Related]
37. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570 [TBL] [Abstract][Full Text] [Related]
38. Receipt of RhD-positive whole blood for life-threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti-D. Sherwood MR; Clayton S; Leeper CM; Yazer M; Moise KJ; Granger ME; Spinella PC Transfusion; 2024 May; 64 Suppl 2():S100-S110. PubMed ID: 38563495 [TBL] [Abstract][Full Text] [Related]
39. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Clausen FB Prenat Diagn; 2014 May; 34(5):409-15. PubMed ID: 24431264 [TBL] [Abstract][Full Text] [Related]